16 October 2026 | Analysis | By Editor Robotics Business NEWS <editor@rbnpress.com>
• In one US health system, median single-use supply costs for robotic gallbladder surgery were $1,309 per case versus $534 for conventional keyhole surgery, with no significant difference in complications or readmissions.
• Instruments are the engine of the business model: in Q2 2026, instruments and accessories brought in $1.73 billion of Intuitive's $2.89 billion in revenue.
• Medicare generally pays for the procedure, not the technique, so the extra cost of robotic assistance often lands on the hospital's budget.
• With Medtronic's Hugo and J&J's Ottava now cleared in the US, competition is shifting from hardware features to cost per procedure, utilization and service models.
For most of the past two decades, the contest in surgical robotics was about what a machine could do: steadier instruments, finer dexterity, sharper three-dimensional vision. Those capabilities still matter. But a second question is now sitting next to them on every hospital procurement committee's agenda: what does each robotic operation actually cost, and is it worth it?
That shift is changing how hospitals buy, how manufacturers design, and how investors judge the growing field of medical robotics companies.
Why Cost Per Procedure Is Now the Metric That Matters
A robotic-assisted surgical system typically brings together four elements: a surgeon console, a patient-side robotic platform, specialized instruments, and a three-dimensional vision system. Together, they let surgeons perform selected procedures through small incisions while keeping direct control of every movement.
The purchase price is only the start. To understand the true total cost of ownership of a surgical robot, hospitals have to account for:
The scale of the recurring piece is visible in the market leader's own numbers. In the second quarter of 2026, Intuitive reported worldwide da Vinci procedure growth of 15 percent, an installed base of 11,710 systems and revenue of $2.89 billion. Of that, $1.73 billion, or roughly 60 percent, came from instruments and accessories that are consumed procedure by procedure. In surgical robotics, the system opens the door; the operations pay the bills.
Robotic vs Laparoscopic Gallbladder Surgery: What the Numbers Show
An October 2026 infographic from The Investor's Almanac captures the challenge through one of the most common operations in general surgery: gallbladder removal, or cholecystectomy.
The figures come from a study published in the journal Surgery in 2025, which tracked cholecystectomies across one US health system from 2017 to 2024. Over that period, robotic cases grew from 0.1 percent to 26 percent of the total. Researchers compared 13,548 laparoscopic (keyhole) operations with 1,258 robotic ones and found:
These numbers describe one health system and one procedure. They are not a universal benchmark: actual costs vary by platform, hospital, instrument policy and contract terms, and robotic surgery may make a stronger case in more complex operations. But the comparison crystallizes the commercial question the whole industry now faces: can robotic surgery deliver enough clinical and operational value to justify its additional cost?
Instrument Costs Become a Competitive Differentiator
Specialized instruments sit at the heart of the surgical robotics business model. Depending on the platform, instruments may carry a limited number of permitted uses, and hospitals must also manage replacement schedules, sterilization, inventory and procurement. These recurring costs weigh most heavily on hospitals with lower procedure volumes, where each robot is used less often.
A systematic review published in Surgical Endoscopy in 2026 looked at the wider question of reusable versus disposable surgical instruments in minimally invasive surgery. Across nine studies covering 4,724 procedures, it found that:
The review was not limited to robotic platforms, but its lesson applies directly to them: instrument design is an economic decision as much as an engineering one. For manufacturers, the opportunity lies in longer-lasting instruments where clinically appropriate, better utilization tracking, faster instrument exchanges, and more efficient sterilization and reprocessing workflows.
Reusable is not automatically better. Infection prevention, regulatory requirements, instrument performance and validated reprocessing procedures must stay at the center of every purchasing decision.
Reimbursement: Who Pays for the Robot?
The financial case for robotic surgery also depends on how procedures are reimbursed. The infographic highlights a zero-dollar additional Medicare payment for using a robot in the illustrated case.
That reflects a broader pattern in the United States: Medicare generally pays for the procedure performed, not the technique used to perform it, and does not provide a separate add-on payment for robotic assistance. It should not, however, be read as a universal rule. Payment arrangements differ by procedure, payer, care setting, country and policy.
Where reimbursement does not cover the extra cost of robotic equipment and instruments, hospitals absorb the difference in their operating budgets. That gives providers a strong incentive to look beyond the sticker price and judge robotic programs on what they deliver across the whole episode of care.
Five Questions Hospitals Should Ask Before Investing in a Surgical Robot
A procedure-by-procedure business case is replacing feature-by-feature comparisons. The most useful assessments tend to answer five questions:
The goal is not simply to negotiate a lower price for the robot. It is to establish whether a surgical robotics program improves clinical and operational performance enough to justify its full cost.
Competition Moves Beyond Hardware
The competitive field has widened sharply. Medtronic received US FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures in December 2025, with general surgery and gynecology expected to follow. Johnson & Johnson secured FDA De Novo authorization for its Ottava system in July 2026 for a range of general surgery procedures, including cholecystectomy, gastric bypass and hernia repair. Ottava is mounted on the operating table with four arms that stow beneath it, and J&J says its footprint is 34 percent smaller than da Vinci's.
Beyond the large players, dozens of companies worldwide are developing surgical robots, including challengers in Europe and Asia that are building their pitch around lower acquisition and per-procedure costs.
As a result, medical robotics companies are increasingly competing on system design, software, workflow integration and service models, not on hardware alone. Modular platforms, smarter instrument utilization, simpler maintenance and tighter integration with hospital information systems can all help providers manage operating costs. Software-assisted planning and data analytics can show hospitals where their robots sit idle and where workflows lose time.
These developments still have to be proven against clinical evidence. Artificial intelligence and automation can support surgical workflows, but robotic-assisted surgery remains dependent on qualified surgeons, careful patient selection and established safety protocols. For manufacturers, demonstrating reliable performance and measurable value across many hospitals may become as important as showcasing technical capability.
Funding and Commercialization: Following the Money
Scaling a surgical robot is capital-intensive. Before a platform reaches broad adoption, its developer has to fund research and development, clinical validation, regulatory approvals, manufacturing, service infrastructure and market access, often over many years.
For investors and hospital partners evaluating medical robotics companies, the useful question is not how much a company has raised or how advanced its platform looks in a demo. It is where the money is going: advancing the technology, generating clinical evidence, expanding manufacturing, building service networks or accelerating commercial rollout. Funding that supports a credible route to clinical adoption and sustainable per-procedure economics is worth far more than funding that only buys more features.
What Comes Next for Surgical Robotics?
The future of surgical robotics will depend on more than technological progress. Manufacturers will need to demonstrate clinical benefit, raise system utilization, control recurring instrument costs, and help hospitals measure the full cost of care.
For healthcare providers, purchasing decisions will increasingly rest on procedure-specific economic assessments rather than equipment specifications or headline prices. For developers, the opportunity lies in systems that pair precision and reliability with efficient workflows and transparent lifecycle costs.
As robotic-assisted surgery matures, the ability to deliver measurable clinical value at a sustainable cost per operation could become one of the industry's most important competitive advantages.
Frequently Asked Questions
Why is robotic surgery more expensive than laparoscopic surgery?
Robotic surgery adds the cost of the system itself, service contracts and specialized instruments with limited permitted uses. In one US study of gallbladder removal, median single-use supply costs were $1,309 for robotic cases versus $534 for laparoscopic cases.
Does Medicare pay more for robotic surgery?
Generally, no. Medicare pays for the procedure performed rather than the technique, and does not provide a separate add-on payment for robotic assistance. Arrangements with other payers and in other countries vary.
Are reusable surgical instruments cheaper than disposable ones?
In general surgery, a 2026 systematic review found reusable instruments were consistently associated with lower per-procedure costs. In some specialties, disposable instruments shortened operating times enough to lower total costs, so the answer depends on the procedure.
What is the total cost of ownership of a surgical robot?
It covers the system purchase or lease, maintenance and service, instruments and accessories, staff training, operating-room time and the procedure volume needed to spread those fixed costs.
Who competes with Intuitive's da Vinci system?
In the US, Medtronic's Hugo (cleared for urologic procedures in December 2025) and Johnson & Johnson's Ottava (authorized for general surgery in July 2026) are the most prominent challengers, alongside dozens of smaller developers worldwide.
